ADX-097 for IgA nephropathy, lupus nephritis, or C3G
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 or older.
- You need to have a kidney biopsy that confirms one of the three diseases being studied.
- Your eGFR (kidney function blood test) must be 30 or higher.
- Your urine protein level must be at least 0.5 g/g (a measure of protein leaking into urine).
- If you take certain blood pressure or diabetes medications, you must be on a stable dose for at least 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
This trial tests an experimental medication (ARGX-121) to see if it can reduce protein in your urine, which is a sign of kidney damage in IgA nephropathy. If you qualify, you may receive the study drug and help researchers learn if it's safe and effective.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.